@movability's anosmia claims need context, not hype
Quick answer
Post-viral olfactory dysfunction affects an estimated 5-10% of COVID-19 patients beyond 12 weeks, based on meta-analyses published through 2023. The primary mechanism involves sustentacular cell injury rather than direct olfactory neuron damage, though persistent cases may involve olfactory bulb inflammation or central processing changes. Olfactory training has level 1b evidence for post-viral cases, but patients with worsening, unilateral, or neurologically complex presentations require formal ENT or neurology evaluation rather than home protocols alone.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @movability actually say?
The creator laid out a rapid-fire explainer on post-viral olfactory dysfunction, covering the biology, a recovery timeline, and a home protocol. They claimed viruses damage "support cells" the olfactory neurons depend on, described a 1-to-12-week recovery window, named parosmia as a sign of "rewiring," and recommended smell training with rose, lemon, clove, and eucalyptus twice daily for 12 weeks. They also said to "never use zinc nasal sprays." The framing is confident and clinical, which raises the question of whether the confidence is earned.
Does the science back this up?
Mostly, yes, with some important nuances. The support cell story is real. COVID-19 and other respiratory viruses preferentially infect sustentacular cells, which are the non-neuronal support cells in the olfactory epithelium, rather than the neurons themselves. This is well-documented. Brann et al. (2020, Chemical Senses) and subsequent work confirmed ACE2 expression is higher in sustentacular cells than in olfactory sensory neurons, which explains why many patients lose smell without full nasal blockage. The timeline the creator gives is broadly consistent with observational data. A 2022 systematic review by Tan et al. in the Laryngoscope found median smell recovery after COVID at around 30 days, with a subset taking 3-plus months. Parosmia appearing during recovery is also well-documented, and the smell training recommendation has actual RCT support behind it. The zinc nasal spray warning is also correct and important.
What did they get wrong or right?
The creator mispronounced and slightly fumbled the term "parosmia," calling it "pyrozmia," which is a minor issue in video but could confuse viewers searching for more information. More substantively, they said viruses "not cut" support cells, which appears to be a garbled transcript of "do cut off" or damage, suggesting the verbal delivery was unclear in the original video. The support cell mechanism is accurate, but calling neuronal recovery "regeneration" oversimplifies it. Olfactory sensory neurons do have regenerative capacity, unlike most CNS neurons, but the process involves basal stem cell repopulation, and in some long-COVID cases there is evidence of persistent epithelial disruption. The creator deserves credit for the zinc nasal spray warning. Intranasal zinc, particularly zinc gluconate products like Zicam, has been linked to permanent anosmia in case reports and a 2009 FDA advisory. That is a genuinely useful safety point that many influencers skip.
What should you actually know?
Post-viral olfactory dysfunction is real, common, and usually temporary but not always. The smell training protocol the creator recommends, four odorants twice daily for at least 12 weeks, is supported by randomized controlled trial data. Hummel et al. (2009, The Laryngoscope) first established this approach, and subsequent studies have replicated positive effects. However, the specific scents matter less than consistency and concentration. More recent research, including work by Pellegrino et al. (2021, JAMA Otolaryngology), suggests high-intensity odorants may outperform the classic Hummel set. One thing the video does not mention: persistent unilateral anosmia or anosmia with headache, visual changes, or other neurological symptoms warrants imaging, not just ENT follow-up. If your smell loss is one-sided and did not follow a clear illness, that is a red flag for something other than post-viral dysfunction. See a doctor before you start sniffing eucalyptus twice a day.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @movability's anosmia claims need context, not hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@movability's anosmia claims need context, not hype should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
Post-viral olfactory dysfunction affects an estimated 5-10% of COVID-19 patients beyond 12 weeks, based on meta-analyses published through 2023.
FormBlends verdict
Post-viral olfactory dysfunction affects an estimated 5-10% of COVID-19 patients beyond 12 weeks, based on meta-analyses published through 2023. The primary mechanism involves sustentacular cell injury rather than direct olfactory neuron damage, though persistent cases may involve olfactory bulb inflammation or central processing changes. Olfactory training has level 1b evidence for post-viral cases, but patients with worsening, unilateral, or neurologically complex presentations require formal ENT or neurology evaluation rather than home protocols alone.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Post-viral olfactory dysfunction affects an estimated 5-10% of COVID-19 patients beyond 12 weeks, based on meta-analyses published through 2023. The primary mechanism involves sustentacular cell injury rather than direct olfactory neuron damage, though persistent cases may involve olfactory bulb inflammation or central processing changes. Olfactory training has level 1b evidence for post-viral cases, but patients with worsening, unilateral, or neurologically complex presentations require formal ENT or neurology evaluation rather than home protocols alone.
- Brann et al. (2020, Chemical Senses) confirmed sustentacular support cells, not olfactory neurons directly, are the primary COVID-19 target in the olfactory epithelium, explaining smell loss without nasal congestion.
- A 2022 Laryngoscope systematic review found median smell recovery after COVID-19 at roughly 30 days, but a meaningful subset takes 3 or more months, and some cases persist beyond a year.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Brann et al. (2020, Chemical Senses) confirmed sustentacular support cells, not olfactory neurons directly, are the primary COVID-19 target in the olfactory epithelium, explaining smell loss without nasal congestion.
- A 2022 Laryngoscope systematic review found median smell recovery after COVID-19 at roughly 30 days, but a meaningful subset takes 3 or more months, and some cases persist beyond a year.
- The 4-scent olfactory training protocol in this video matches the Hummel et al. (2009) RCT design, which is the most-cited evidence base for this intervention and has been replicated in post-COVID cohorts.
- The FDA issued a 2009 safety warning on intranasal zinc products after reports of permanent smell loss; the creator's warning to avoid zinc nasal sprays is clinically valid.
- Parosmia, where familiar smells are distorted or smell unpleasant, is a recognized phase of olfactory recovery and often signals active neural rewiring rather than worsening, according to long-COVID clinic data.
- Unilateral anosmia, smell loss with no preceding illness, or anosmia accompanied by headache or neurological symptoms requires imaging and specialist evaluation, not home smell training.
- Pellegrino et al. (2021, JAMA Otolaryngology) suggested higher-intensity odorants may improve training outcomes over the classic rose-lemon-clove-eucalyptus set, though any consistent high-quality odorant exposure likely confers benefit.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Movability · TikTok creator
16.4K views on this video
Lost your sense of smell after being sick? This is called post-viral olfactory dysfunction (anosmia). It’s common after colds, flu, and especially COVID. I pulled this from peer-reviewed studies, ENT
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Movability, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.